Skip to main content

Closed

PHAR: Pharming Group N.V. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Mixed

Revenue growth+21.1% / yr

Operating margin4.0%

ROIC2.2%

Financially safe

Stretched

Debt / equity0.49×

Interest coverage0.0×

Current ratio3.01×

Valuation

Unrated

P/E ratio68.9×

Pharming Group N.V.

PHARNASDAQ Global Market·USD·Closed

Pharming Group N.V.

PHARNASDAQ·USD·Closed

$10.08

−6.23%

$10.08

−$0.67 (6.23%)

52W Range

4thpctl

Volume

2.48×avg

Mkt Cap

713.44MUSD

P/E

68.9TTM

Div Yield

–ann

52W Range

4thpctl

Volume

2.48×avg

Market Cap

713.44MUSD

P/E Ratio

68.9TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings